Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2

AbbVie

Status: Completed

Conditions: Chronic Hepatitis C Virus

Study type: Observational

Funder types: Industry

Identifiers

NCT02945228

P15-764

Details and patient eligibility

About

The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir with ribavirin used for participants infected with chronic hepatitis C virus (HCV) genotype 2 in daily practice in Japan.

Enrollment: 449 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HCV genotype 2 participants treated with paritaprevir/ritonavir/ombitasvir plus ribavirin in daily practice.

Exclusion criteria

• Participants who have been previously treated with paritaprevir/ritonavir/ombitasvir and ribavirin.

Trial design

449 participants in 1 patient group

Chronic infection of hepatitis C virus (HCV) genotype 2

Description:

Participants with confirmed chronic HCV genotype 2, receiving paritaprevir/ritonavir/ombitasvir and ribavirin according to standard of care and in line with the current local label